We are excited to spotlight the Microfluidics Innovation Center in our newest pilot feature!
Working alongside deeptech bio innovator Inside Therapeutics, the pilot focuses on achieving precision biochemistry via next generation microflow control. By developing advanced microfluidic flow systems, this collaboration is refining the synthesis of therapeutic lipid nanoparticles, the essential delivery vehicles for RNA vaccines and genetic medicines. The innovation enhances batch-to-batch repeatability and eliminates raw material loss, streamlining the journey of advanced therapeutics from early stage screening directly to clinical manufacturing.
Read the full interview below to discover how was their journey in the InnoMatch programme and their expectations for the future.
Get a look at their technology in our latest brochure, available below. Discover exactly how this solution works, who it is designed for, and how you can get in touch if you would like to connect!
What are your expectations as your solution moves into the assessment phase? And your lessons learned?
In the assessment phase, we expect to confirm that Galileo’s technical performance translates into clear added value for LNP production, especially in terms of process control, reproducibility and platform reliability.
One key lesson is that early integration with an industrial partner is extremely valuable, but it requires flexibility: product architectures, use cases and development roadmaps may still evolve during the project.
Another important learning is that GMP readiness is essential before broader industrial adoption in biopharmaceutical markets.
How has InnoMatch helped you achieve your business goals? What have you valued the most so far?
InnoMatch has been a strong accelerator for Galileo’s commercialisation.
It helped MIC initiate a first structured industrial validation and joint development project around the technology, which is usually difficult to trigger without a first industrial reference.
The programme provided funding, deadlines and external follow-up, helping maintain momentum and partner engagement.
What we valued most is the structured and reassuring framework it creates for all parties during a critical early adoption phase.
What does success look like for you beyond this pilot and the InnoMatch programme?
Success would mean confirming Galileo’s added value during the assessment phase, establishing a long-term industrial collaboration around the technology, and using this first industrial reference to accelerate the deployment of Galileo-based solutions across multiple markets.
Beyond the pilot, our objective is to make Galileo a reference flow-sensing technology for microfluidic instrumentation, biopharmaceutical production and metrology applications.
Learn more about the Microfluidics Innovation Center pilot here.